Award number/project title: W81XWH2110076/B7-H3 (CD276) as a therapeutic target in lethal prostate cancers
Ended Project Grant Awarded Last action
- Award ID
- W81XWH2110076
- Recipient
-
Institute Of Cancer Research: Royal Cancer Hospital (The) UEI KXJBJJGTZTU3
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $699,534
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date
- Place of performance
- Great Britain, United Kingdom
Award details come from USAspending.gov.
About this award
The Department of the Army Medical Command awarded a $699,534 project grant to the Institute of Cancer Research: Royal Cancer Hospital under the Military Medical Research and Development program (CFDA 12.420). The three-year grant will support research on B7-H3 (CD276) as a therapeutic target in lethal prostate cancers. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical research that investigates medical solutions for battlefield wounds. This award will advance those goals by funding basic and applied research exploring potential new treatment approaches for aggressive forms of prostate cancer. All work will be conducted in Great Britain by investigators at the Institute of Cancer Research.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $699,534 |
Quick answers
Who received award W81XWH2110076?
W81XWH2110076 was awarded to Institute Of Cancer Research: Royal Cancer Hospital (The) by Medical Command (Department of the Army) on May 15, 2021.
How much is award W81XWH2110076 worth?
$699,534 has been obligated on W81XWH2110076.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award